COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE STUDIES LOCATION PRODUCT
Ability Pharmaceuticals ABTL0812 Biodrugs/ Drugs Cancer Lung, Endometrial and Pancreatic Cancer 4PhII Espa√Īa, EEUU, Francia e Israel ABTL0812
Therapeutic area: Cancer
Accure Therapeutics ACT-01 Biodrugs/ Drugs Central Nervous System
Ophthalmology and optometry
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis 3PhI ACT-01
Therapeutic area: Central Nervous System
Ophthalmology and optometry
Almirall Efinaconazole Biodrugs/ Drugs Dermatology
Infections
Onychomicosis 6Reg. Efinaconazole
Therapeutic area: Dermatology
Infections
Almirall Lebrikizumab Biodrugs/ Drugs Dermatology Atopic Dermatitis 5PhIII EU Lebrikizumab
Therapeutic area: Dermatology
Almirall Protein degraders Biodrugs/ Drugs Dermatology Dermatological conditions 1NRP Protein degraders
Therapeutic area: Dermatology
Almirall Klisyri Biodrugs/ Drugs Dermatology Actinic Keratosis 5PhIII USA Klisyri
Therapeutic area: Dermatology
Almirall Non-viral gene therapy Gene / Cell Therapy Dermatology Orphan dermatological conditions 1NRP Non-viral gene therapy
Therapeutic area: Dermatology
Almirall Wynzora Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Psoriasis 6Reg. EU Wynzora
Therapeutic area: Autoimmune & Inflammation
Dermatology
Almirall Tirbanibulin Biodrugs/ Drugs Dermatology Actinic keratosis 6Reg. EU Tirbanibulin
Therapeutic area: Dermatology
Almirall Bispecific Abs Biodrugs/ Drugs Dermatology Atopic dermatitis 1NRP Bispecific Abs
Therapeutic area: Dermatology
Almirall Translational Read-Through Inducers Biodrugs/ Drugs Dermatology Dystrophic Epidermolysis Bullosa 1NRP Translational Read-Through Inducers
Therapeutic area: Dermatology
Almirall Bispecific anti_IL36 Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Inflammatory skin diseases 1NRP Bispecific anti_IL36
Therapeutic area: Autoimmune & Inflammation
Dermatology
Almirall Sarecycline Biodrugs/ Drugs Dermatology Acne 5PhIII China Sarecycline
Therapeutic area: Dermatology
Aptatargets APTOLL-02 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
Multiple Sclerosis 2RP APTOLL-02
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
Aptatargets APTOLL-01 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
Acute Ischemic Stroke 4PhII Spain, France, Germany APTOLL-01
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
Aptatargets APTOLL-02 Biodrugs/ Drugs Autoimmune & Inflammation
Infections
Respiratory and Pulmonary system
COVID-19, Acute Respiratory Distress Syndrome (ARDS) 3PhI Spain APTOLL-02
Therapeutic area: Autoimmune & Inflammation
Infections
Respiratory and Pulmonary system
Aptatargets APTOLL-01 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Acute Myocardial Infarction 2RP APTOLL-01
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
APTUS Biotech AptaMnkQ2 Biodrugs/ Drugs Cancer
Womenīs health
ApMNKQ2 is a 29-nucleotide aptamer targeting kinase MNK1b that have shown capable of reducing tumor size, inhibiting tumor cell proliferation and inducing apoptosis in an orthotopic model of triple-negative breast cancer. 1NRP AptaMnkQ2
Therapeutic area: Cancer
Womenīs health
APTUS Biotech CAT-ApMnkQ2 Biodrugs/ Drugs Cancer Aptusbiotech intend to develop novel therapies against Anaplastic Thyroid Cancer (CAT) based on our aptamer apMNKQ2 improving its design and applying updated formulations 1NRP CAT-ApMnkQ2
Therapeutic area: Cancer
Araclon Biotech ABvac40 Vaccines Central Nervous System Alzheimer's Disease 4PhII Spain, France, Italia, Sweeden ABvac40
Therapeutic area: Central Nervous System
Archivel Farma RUTI Vaccines Infections Drug Susceptible (DS)- Tuberculosis (TB) Drug Resistance (DR)- TB Latent TB infection (LTBI) 4PhII Ukraine, India, Argentina, Spain and Southafrica RUTI
Therapeutic area: Infections
Archivel Farma RUTI Biodrugs/ Drugs Cancer Non-muscle Invasive Bladder Cancer (NMIBC) 3PhI Spain RUTI
Therapeutic area: Cancer
Arthex Biotech Anti-miRNA Biodrugs/ Drugs Musculoskeletal Disorders Osteoarthritis 1NRP spain Anti-miRNA
Therapeutic area: Musculoskeletal Disorders
Arthex Biotech ARTHEx-01 Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
Myotonic dystrophy type 1 (DM1) 2RP Spain, UK, France, Germany ARTHEx-01
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
ATRYS HEALTH NILO1 Biodrugs/ Drugs Cancer
Central Nervous System
Brain tumor and brain lesions 1NRP Spain NILO1
Therapeutic area: Cancer
Central Nervous System
Bionos Biotech SL Pytren 4Q - Scorpio Therapeutics Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Pytren 4Q se presenta como una terapia sintomática para la enfermedad huárfana de Huntington mediante la reducciín de los séntomas por activaciín y estimulaciín de la autofagia y de la actividad proteasímica. Es un compuesto antioxidante, activador 1NRP Pytren 4Q - Scorpio Therapeutics
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
CIBER Method for precise gene editing of the COL7A1 gene by homologous recombination-based editing Gene / Cell Therapy Dermatology Epidermolysis Bullosa 1NRP Spain Method for precise gene editing of the COL7A1 gene by homologous recombination-based editing
Therapeutic area: Dermatology
CIBER Combined use of biotine and thiamine for prevention and treatment of Hungtington Disease Biodrugs/ Drugs Central Nervous System CSIC and the CIBERNED have determined that the combined administration of biotin and thiamine is capable of improving motor symptoms and reducing striatal atrophy associated with Huntington Disease (HD). 1NRP Spain Combined use of biotine and thiamine for prevention and treatment of Hungtington Disease
Therapeutic area: Central Nervous System
CIBER Pharmaceutical composition for use in the treatment of depression by the intranasal via Biodrugs/ Drugs Central Nervous System Treatment for depression 1NRP Pharmaceutical composition for use in the treatment of depression by the intranasal via
Therapeutic area: Central Nervous System
CIBER Gene editing medicinal product for Epidermolysis Bullosa Gene / Cell Therapy Dermatology Epidermolysis Bullosa. Autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by Crispr/Cas9-mediated 2RP Spain Gene editing medicinal product for Epidermolysis Bullosa
Therapeutic area: Dermatology
CIBER COMPOUNDS FOR TREATING HELICOBACTER PYLORI AND CAMPYLOBACTER JEJUNI INFECTION Biodrugs/ Drugs Digestive System
Infections
The present invention describes new bioactive compounds with antimicrobial activity against Helicobacter pylori (H. pylori) and Campylobacter jejuni (C. jejuni) by acting specifically on the protein HsrA (essential for cell viability). 1NRP Spain COMPOUNDS FOR TREATING HELICOBACTER PYLORI AND CAMPYLOBACTER JEJUNI INFECTION
Therapeutic area: Digestive System
Infections
CIBER Gene Therapy for the treatment of Diamond-Blackfan Anemia Gene / Cell Therapy Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
Diamond-Blackfan Anemia 2RP Europe Gene Therapy for the treatment of Diamond-Blackfan Anemia
Therapeutic area: Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
CIBER APTAMERS FOR THE TREATMENT OF CONGENITAL AND ACQUIRED NEUTROPENIAS Biodrugs/ Drugs Cancer
Genetic Diseases and Dysmorphic syndromes
Others
Aptamers for the treatment of congenital and acquired Neutropenias 1NRP Spain APTAMERS FOR THE TREATMENT OF CONGENITAL AND ACQUIRED NEUTROPENIAS
Therapeutic area: Cancer
Genetic Diseases and Dysmorphic syndromes
Others
CIBER Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues Biodrugs/ Drugs Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Obesity, atherosclerosis 2RP Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
Therapeutic area: Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
CIBER GUT MICROBIOTA COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF A MENTAL DISORDER Biodrugs/ Drugs Others The present invention is a gut microbiota composition comprising a wide range of species of genus with a vast array of applications for use in the specific prevention and/or treatment of a mental disorder with memory impairment in a subject. 1NRP Spain GUT MICROBIOTA COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF A MENTAL DISORDER
Therapeutic area: Others
CIBER BACTERIOPHAGUE FOR THE PREVENTION AND TREATMENT OF A MENTAL DISORDERS Biodrugs/ Drugs Central Nervous System Mental health 2RP BACTERIOPHAGUE FOR THE PREVENTION AND TREATMENT OF A MENTAL DISORDERS
Therapeutic area: Central Nervous System
CIBER Pharmaceutical compositions for the prevention of Charcot-Marie-Tooth disease Biodrugs/ Drugs Central Nervous System Charcot-Marie-Tooth disease. 1NRP Spain Pharmaceutical compositions for the prevention of Charcot-Marie-Tooth disease
Therapeutic area: Central Nervous System
CIBER CARVACROL AS DISINFECTANT AGAINST LEGIONELLA Biodrugs/ Drugs Infections
Others
Legionella 1NRP CARVACROL AS DISINFECTANT AGAINST LEGIONELLA
Therapeutic area: Infections
Others
CIBER GENE EDITING FOR THE TREATMENT OF EWING’S SARCOMA Gene / Cell Therapy Cancer EWING’S SARCOMA 1NRP Spain GENE EDITING FOR THE TREATMENT OF EWING’S SARCOMA
Therapeutic area: Cancer
CIBER DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF ¬† Biodrugs/ Drugs Central Nervous System CSIC, CIBERNED and UAM ‚Äď Modulators of the neuronal calcium sensor DREAM (Downstream Regulator Element antagonist modulator). These compounds may be useful in pathologies associated for Huntington‚Äôs disease treatment 1NRP Spain DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF ¬†
Therapeutic area: Central Nervous System
CIBER MicroRNA for the treatment of obesity Gene / Cell Therapy Metabolic / Endocrinology Obesity treatment 1NRP MicroRNA for the treatment of obesity
Therapeutic area: Metabolic / Endocrinology
CIBER COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS Biodrugs/ Drugs Metabolic / Endocrinology obesity-related metabolic disorders, obesity-related tissue dysfunction 1NRP COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
Therapeutic area: Metabolic / Endocrinology
CIBER GENETICALLY MODIFIED MSCs overexpressing CXCR4-IL10 AS ALTERNATIVE TREATMENT FOR GRAFT versus HOST DISEASE Gene / Cell Therapy Autoimmune & Inflammation GRAFT versus HOST DISEASE 2RP Spain GENETICALLY MODIFIED MSCs overexpressing CXCR4-IL10 AS ALTERNATIVE TREATMENT FOR GRAFT versus HOST DISEASE
Therapeutic area: Autoimmune & Inflammation
CIBER Pharmaceutical composition comprising 5-dodecanolide, its preparation and its use Biodrugs/ Drugs Autoimmune & Inflammation anti-inflammatory diseases 1NRP Pharmaceutical composition comprising 5-dodecanolide, its preparation and its use
Therapeutic area: Autoimmune & Inflammation
DIOMUNE SL IV1303 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV 2RP IV1303
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
FERRER FNP-117 Gene / Cell Therapy Central Nervous System Spinal Cord Injury 4PhII FNP-117
Therapeutic area: Central Nervous System
FERRER FNP-120 Biodrugs/ Drugs Ophthalmology and optometry Diabetic Retinopathy 4PhII FNP-120
Therapeutic area: Ophthalmology and optometry
FERRER FNP-150 Biodrugs/ Drugs Central Nervous System Parkinson 4PhII FNP-150
Therapeutic area: Central Nervous System
FERRER FNP-202 Biodrugs/ Drugs Respiratory and Pulmonary system Pulmonary Arterial Hypertension 5PhIII FNP-202
Therapeutic area: Respiratory and Pulmonary system
FERRER FNP-911 Biodrugs/ Drugs Analgesia & Pain Osteoarthritis 1NRP FNP-911
Therapeutic area: Analgesia & Pain
FERRER FNP-010 Biodrugs/ Drugs Central Nervous System Cyclic Vomiting Syndrome 4PhII FNP-010
Therapeutic area: Central Nervous System
FERRER FNP-080 Biodrugs/ Drugs Cardiovascular and circulatory systems Secondary prevention of cardiovascular accidents 3PhI FNP-080
Therapeutic area: Cardiovascular and circulatory systems
FERRER FNP-122 Biodrugs/ Drugs Central Nervous System Neuromotor disorders 5PhIII FNP-122
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD GENYO-20001 CRISPNA, A NEW TOOL FOR GENOME EDITING AND DIAGNOSIS Gene / Cell Therapy Others Genome Editing and Diagnosis 1NRP GENYO-20001 CRISPNA, A NEW TOOL FOR GENOME EDITING AND DIAGNOSIS
Therapeutic area: Others
FUND. PROGRESO Y SALUD CABIMER- 21001 Use of melatonin to improve the therapeutic potential of mesenchymal stem cells in cancer Biodrugs/ Drugs Cancer Cancer 1NRP CABIMER- 21001 Use of melatonin to improve the therapeutic potential of mesenchymal stem cells in cancer
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FISEVI-13002 CANNABIOTICS Biodrugs/ Drugs Cancer Multiple myeloma 2RP FISEVI-13002 CANNABIOTICS
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD CABIMER-19002 NON-VIRAL VECTORS FROM MESOPOROUS NANOPARTICLES FOR THEIR APPLICATION IN GENE THERAPY FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA Gene / Cell Therapy Ophthalmology and optometry Degenerative diseases of the retina 1NRP CABIMER-19002 NON-VIRAL VECTORS FROM MESOPOROUS NANOPARTICLES FOR THEIR APPLICATION IN GENE THERAPY FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA
Therapeutic area: Ophthalmology and optometry
FUND. PROGRESO Y SALUD FIBICO-14003 LISED OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF MUSCULAR SKELETAL INJURIES Gene / Cell Therapy Musculoskeletal Disorders Musculoskeletal disorders 1NRP FIBICO-14003 LISED OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF MUSCULAR SKELETAL INJURIES
Therapeutic area: Musculoskeletal Disorders
FUNDACI√ďN JIM√ČNEZ D√ćAZ (Instituto de Investigaci√≥n Sanitaria) Chemical Scalpel Biodrugs/ Drugs Cancer Peritoneal carcinomatosis 2RP Spain Chemical Scalpel
Therapeutic area: Cancer
FUNDACI√ďN JIM√ČNEZ D√ćAZ (Instituto de Investigaci√≥n Sanitaria) Lentiviral vector Gene / Cell Therapy Genetic Diseases and Dysmorphic syndromes In vivo lentiviral gene therapy for the treatment of primary hyperoxaluria type 1 2RP Spain Lentiviral vector
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
FUNDACI√ďN JIM√ČNEZ D√ćAZ (Instituto de Investigaci√≥n Sanitaria) New antigenic trigger Biodrugs/ Drugs Cardiovascular and circulatory systems Method for the diagnosis and/or treatment of atherosclerosis 1NRP Spain New antigenic trigger
Therapeutic area: Cardiovascular and circulatory systems
FUNDACI√ďN JIM√ČNEZ D√ćAZ (Instituto de Investigaci√≥n Sanitaria) New genetic- engineering molecules to CKD Biodrugs/ Drugs Kidney and Genitourinary system Therapy in the prevention of premature ageing related to Chronic Kidney Disease 1NRP New genetic- engineering molecules to CKD
Therapeutic area: Kidney and Genitourinary system
FUNDACI√ďN JIM√ČNEZ D√ćAZ (Instituto de Investigaci√≥n Sanitaria) Treatment of epidermolysis bullosa Gene / Cell Therapy Genetic Diseases and Dysmorphic syndromes Genome editing in primary keratinocytes for Epidermolysis bullosa treatment 3PhI Spain Treatment of epidermolysis bullosa
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
FUNDACI√ďN JIM√ČNEZ D√ćAZ (Instituto de Investigaci√≥n Sanitaria) Pyruvate kinase deficiency (PKD) Gene / Cell Therapy Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
Pyruvate kinase deficiency gene editing treatment method 3PhI Spain Pyruvate kinase deficiency (PKD)
Therapeutic area: Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
FUNDACI√ďN JIM√ČNEZ D√ćAZ (Instituto de Investigaci√≥n Sanitaria) Hematopoietic stem cell transplantation (HSCT) Gene / Cell Therapy Blood and Lymphatic systems
Cancer
Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation 3PhI Spain Hematopoietic stem cell transplantation (HSCT)
Therapeutic area: Blood and Lymphatic systems
Cancer
Fundacion MEDINA MDN-005 Biodrugs/ Drugs Central Nervous System
Musculoskeletal Disorders
Amyotrophic lateral sclerosis†(ALS) 1NRP MDN-005
Therapeutic area: Central Nervous System
Musculoskeletal Disorders
Fundacion MEDINA MDN-088 Biodrugs/ Drugs Cancer Breast, Colon & Lung Cancer 1NRP MDN-088
Therapeutic area: Cancer
Fundacion MEDINA MDN-0090 Biodrugs/ Drugs Cancer Pancreatic Cancer 1NRP MDN-0090
Therapeutic area: Cancer
Highlight Therapeutics BO-112 Biodrugs/ Drugs Cancer Solid tumors in patients with liver metastasis from colorectal cancer or gastric/gastro-esophageal junction cancer. Patients with advanced and/or metastatic melanoma. 4PhII BO-112
Therapeutic area: Cancer
Histocell HC016 Biodrugs/ Drugs Central Nervous System Acute Spinal Cord Injury 4PhII HC016
Therapeutic area: Central Nervous System
Histocell HR004 Biodrugs/ Drugs Musculoskeletal Disorders Bone Regeneration 4PhII HR004
Therapeutic area: Musculoskeletal Disorders
Histocell HR016 Biodrugs/ Drugs Respiratory and Pulmonary system Acute Lung Injury 4PhII HR016
Therapeutic area: Respiratory and Pulmonary system
Institut Quimic de Sarrià (IQS) Chondro-implant Gene / Cell Therapy Cardiovascular and circulatory systems Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure 1NRP Chondro-implant
Therapeutic area: Cardiovascular and circulatory systems
Institut Quimic de Sarrià (IQS) Cardio-implant Gene / Cell Therapy Cardiovascular and circulatory systems PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct 1NRP Cardio-implant
Therapeutic area: Cardiovascular and circulatory systems
IRYCIS New aptamers for the treatment of stroke Biodrugs/ Drugs Central Nervous System Stroke 4PhII New aptamers for the treatment of stroke
Therapeutic area: Central Nervous System
IRYCIS New compound for the treatment of isquemical stroke Biodrugs/ Drugs Central Nervous System Isquemic stroke 1NRP Spain New compound for the treatment of isquemical stroke
Therapeutic area: Central Nervous System
Laminar Pharma LAMAC2 Biodrugs/ Drugs Infections Respiratory infections 3PhI LAMAC2
Therapeutic area: Infections
Laminar Pharma LAMPEC11 Biodrugs/ Drugs Cancer Brain cancer 1NRP LAMPEC11
Therapeutic area: Cancer
Laminar Pharma LAM182 Biodrugs/ Drugs Cancer Pancreas 4PhII LAM182
Therapeutic area: Cancer
Laminar Pharma LAM561 Biodrugs/ Drugs Cancer Glioma and other solid tumours 5PhIII LAM561
Therapeutic area: Cancer
Laminar Pharma LAM30171 Biodrugs/ Drugs Cancer
Metabolic / Endocrinology
Metabolic Diseases, cancer 1NRP LAM30171
Therapeutic area: Cancer
Metabolic / Endocrinology
Laminar Pharma LAM205A1 Biodrugs/ Drugs Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
Cardiovascular and Metabolic Diseases, CNS, 1NRP LAM205A1
Therapeutic area: Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
Laminar Pharma LAM181 Biodrugs/ Drugs Central Nervous System Spinal Cord Injury, Pain. Global rigths outlicensed to a third party biotech company 4PhII LAM181
Therapeutic area: Central Nervous System
Laminar Pharma LAM226A1 Biodrugs/ Drugs Central Nervous System Alzheimer's Disease 2RP LAM226A1
Therapeutic area: Central Nervous System
Laminar Pharma LAM204A1 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Inflammation, Cardiovascular 1NRP LAM204A1
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Leitat Anti-S100A4 Biodrugs/ Drugs Cancer
Metabolic / Endocrinology
Anti-cancer Anti-metastasis Anti-fibrosis 1NRP Anti-S100A4
Therapeutic area: Cancer
Metabolic / Endocrinology
Leitat COVID Biodrugs/ Drugs Infections Neutralizing antibodies 1NRP COVID
Therapeutic area: Infections
Leukos Biotech LB208 Biodrugs/ Drugs Cancer Specific and selective HTR1B antagonist, providing a antitumoral agent with potential to address current unmet needs in solid tumors such as TNBC, Hepatocellular Carcinoma or Ovarian Cancer, and in hematological malignancies such as AML or MDS. 2RP Spain LB208
Therapeutic area: Cancer
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System
Metabolic / Endocrinology
Acute X-linked Adrenoleukodystrophy (cALD; cerebral ALD) 5PhIII Spain, Germany, France MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Metabolic / Endocrinology
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System
Metabolic / Endocrinology
Chronic X-linked Adrenoleukodystrophy (AMN; Adrenomyeloneuropathy) 6Reg. MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Metabolic / Endocrinology
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System Friedreich's Ataxia 4PhII MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Neurofix NFX91 Biodrugs/ Drugs Others Sleep disorders 1NRP NFX91
Therapeutic area: Others
Neurofix NFX88 Biodrugs/ Drugs Analgesia & Pain
Central Nervous System
Neuropathic pain 4PhII Spain NFX88
Therapeutic area: Analgesia & Pain
Central Nervous System
Neurofix NFX81 Biodrugs/ Drugs Central Nervous System Spinal Cord Injuries 2RP Spain NFX81
Therapeutic area: Central Nervous System
ONA Therapeutics ONA-1 Biodrugs/ Drugs Cancer Advanced cancer 1NRP ONA-1
Therapeutic area: Cancer
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Kabuki Syndrome Clinical Trial "HOPE" - in preparation IND 1H22 / FPI 1H22 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Iadademstat (ORY-1001) - Selective LSD1 inhibitor Biodrugs/ Drugs Cancer ED-SCLC 1L Clinical Trial "STELLAR" (Combo with ICI) In preparation IND 1H22 7 FPI 2H22 4PhII Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area: Cancer
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Schizophrenia (Negative Symptoms & Cognition) Clinical Trial "EVOLUTION" - recruiting 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System SetD1A Compass related SCZ New Clinical Trial - Under study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Iadademstat (ORY-1001) - Selective LSD1 inhibitor Biodrugs/ Drugs Cancer NETs R/R Clinical Trial "NET Basket" (Combo w other agents) In preparation IND 1H22 / FPI 2H22 4PhII Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area: Cancer
Oryzon Iadademstat (ORY-1001) - Selective LSD1 inhibitor Biodrugs/ Drugs Cancer AML - R/R-Flt3 mut+ Clinical Trial "FRIDA" (combo w gilteritinib) IND approved FPI 1H22 3PhI Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area: Cancer
Oryzon Iadademstat (ORY-1001) - Selective LSD1 inhibitor Biodrugs/ Drugs Cancer AML - 1L Elderly / Unfit Clinical Trial "ALICE" (Combo w azacitidine) Ongoing - fully enrolled 2H22 EHA/ASH Final Data 4PhII Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area: Cancer
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Borderline Personality Disorder (BPD) Clinical Trial "PORTICO" - recruiting Interim Analysis 4Q22 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Selective HDAC-6i Biodrugs/ Drugs Others Undisclosed 2RP Selective HDAC-6i
Therapeutic area: Others
Oryzon Other selective LSD1i Biodrugs/ Drugs Others Non-Oncological 2RP Other selective LSD1i
Therapeutic area: Others
PaloBiofarma PBF-999 Biodrugs/ Drugs Cancer Solid Tumors 3PhI Spain PBF-999
Therapeutic area: Cancer
PaloBiofarma PBF-509 Biodrugs/ Drugs Cancer
Central Nervous System
Lung Cancer 4PhII Spain PBF-509
Therapeutic area: Cancer
Central Nervous System
PaloBiofarma PBF680 Biodrugs/ Drugs Respiratory and Pulmonary system Asthma 4PhII Spain PBF680
Therapeutic area: Respiratory and Pulmonary system
Peaches Biotech PRS TENOBOOST Biodrugs/ Drugs Musculoskeletal Disorders Tendon regeneration 2RP PRS TENOBOOST
Therapeutic area: Musculoskeletal Disorders
Peaches Biotech PRS OSTEOBOOST Biodrugs/ Drugs Musculoskeletal Disorders Bone regeneration 2RP PRS OSTEOBOOST
Therapeutic area: Musculoskeletal Disorders
Peaches Biotech PRS SCARBOOST Biodrugs/ Drugs Others Advanced cell therapy drug with adult mesenchymal and fibroblast stem cells and fibroblast PRS for surgical scar treatment 2RP PRS SCARBOOST
Therapeutic area: Others
Peaches Biotech OPT CELL Biodrugs/ Drugs Cancer Pancreas cancer treatment and other solid cancer 2RP OPT CELL
Therapeutic area: Cancer
Peaches Biotech PRS CK STORM Biodrugs/ Drugs Autoimmune & Inflammation
Infections
Cytoquine storm in COVID-19, pancreatis and sepsis 2RP PRS CK STORM
Therapeutic area: Autoimmune & Inflammation
Infections
Peaches Biotech PRS NEUROPAINBOOST Biodrugs/ Drugs Analgesia & Pain Neuropathic pain treatment 2RP PRS NEUROPAINBOOST
Therapeutic area: Analgesia & Pain
Peaches Biotech PRS MIOBOOST Biodrugs/ Drugs Musculoskeletal Disorders Muscle tissue regeneration 2RP PRS MIOBOOST
Therapeutic area: Musculoskeletal Disorders
Peptomyc OMO-103 Biodrugs/ Drugs Cancer First pan-MYC inhibitor in the clinic 3PhI Spain OMO-103
Therapeutic area: Cancer
PharmaMar ZEPZELCA (lurbinectedin) + Atezolizumab Biodrugs/ Drugs Cancer Small cell lung cancer 2nd line IST Combos 4PhII ZEPZELCA (lurbinectedin) + Atezolizumab
Therapeutic area: Cancer
PharmaMar PM14 (ecubectedin) Biodrugs/ Drugs Cancer Solid tumors 4PhII Europe and USA PM14 (ecubectedin)
Therapeutic area: Cancer
PharmaMar PM14 (ecubectedin) Biodrugs/ Drugs Cancer Soft tissue sarcoma IST 3PhI PM14 (ecubectedin)
Therapeutic area: Cancer
PharmaMar ZEPZELCA (lurbinectedin) + IO Biodrugs/ Drugs Cancer Mesothelioma >= 2nd line 4PhII ZEPZELCA (lurbinectedin) + IO
Therapeutic area: Cancer
PharmaMar PM14 (ecubectedin) combination trials Biodrugs/ Drugs Cancer Solid tumors 3PhI PM14 (ecubectedin) combination trials
Therapeutic area: Cancer
PharmaMar ZEPZELCA (Lurbinectedin) + Irinotecan/Topotecan Biodrugs/ Drugs Cancer Small cell lung cancer 2nd line 5PhIII Europe and USA ZEPZELCA (Lurbinectedin) + Irinotecan/Topotecan
Therapeutic area: Cancer
REIG JOFRE P0223 Biodrugs/ Drugs Dermatology Skin infection 6Reg. Spain P0223
Therapeutic area: Dermatology
REIG JOFRE P0265 Biodrugs/ Drugs Dermatology Skin infections 5PhIII Spain, Mexico P0265
Therapeutic area: Dermatology
Sanifit SNF472 Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Calciphylaxis 5PhIII SNF472
Therapeutic area: Cardiovascular and circulatory systems
Metabolic / Endocrinology
Sanifit SNF472 Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Peripheral Arterial Disease (dialysis) 5PhIII SNF472
Therapeutic area: Cardiovascular and circulatory systems
Metabolic / Endocrinology
SOM Biotech SOM0061 Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
COVID-19 4PhII SOM0061
Therapeutic area: Infections
Respiratory and Pulmonary system
SOM Biotech SOM1311 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Phenylketonuria 4PhII Phase 2a: EU SOM1311
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
SOM Biotech SOM3355 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Chorea in Huntington's disease 4PhII Phase IIb: EU SOM3355
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
SOM Biotech SOM0034 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
Confidential 2RP SOM0034
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
SOM Biotech SOM0045 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Confidential 2RP SOM0045
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
SOM Biotech SOM3366 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
Tardive Dyskinesia 3PhI Phase 1: EU SOM3366
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
SOM Biotech SOM0044 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Confidential 2RP SOM0044
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
SOM Biotech SOM0208 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Confidential 2RP SOM0208
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Sylentis Tivanisir√°n (SYL1001) Biodrugs/ Drugs Ophthalmology and optometry Dry Eye Syndrome 5PhIII Tivanisir√°n (SYL1001)
Therapeutic area: Ophthalmology and optometry
Sylentis SYL1801 Biodrugs/ Drugs Ophthalmology and optometry Macular degeneration 3PhI SYL1801
Therapeutic area: Ophthalmology and optometry
VCN Biosciences VCN-02 Gene / Cell Therapy Cancer Solid Tumors 1NRP VCN-02
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Head & Neck Cancer 3PhI Spain VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-11 Gene / Cell Therapy Cancer Solid Tumors 2RP VCN-11
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Retinoblastoma 3PhI Spain VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer In combination with CAR-T cells for mesothelin positive tumors (ovarian/ pancreatic) 3PhI USA VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer
Central Nervous System
High-grade brain tumours 3PhI UK VCN-01
Therapeutic area: Cancer
Central Nervous System
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Pancreatic cancer 4PhII Spain, Germany, USA VCN-01
Therapeutic area: Cancer
Vivia Biotech Vivia 011 Biodrugs/ Drugs Metabolic / Endocrinology Obesity, Diabetes 1NRP Vivia 011
Therapeutic area: Metabolic / Endocrinology
Vivia Biotech Vivia 009 Biodrugs/ Drugs Blood and Lymphatic systems
Central Nervous System
Non Hodgkin Lymphoma, CNS 2RP Europe Vivia 009
Therapeutic area: Blood and Lymphatic systems
Central Nervous System
ZENDAL MTBVAC Vaccines Infections
Respiratory and Pulmonary system
MTBVAC vaccine is based on a genetically attenuated strain of a clinical isolate of M. tuberculosis manufactured by BIOFABRI (Zendal Corp.). MTBVAC is in Phase 3 in newborn infants in South Africa, Senegal and Madagascar and finished Phase2a in adults 5PhIII MTBVAC
Therapeutic area: Infections
Respiratory and Pulmonary system